Viet Nam
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 6.6 (6.30 - 6.92) | 2019 | Modelled | IHME |
| 6.73 (6.45 - 7.03) | 2018 | Modelled | IHME |
| 6.88 (6.56 - 7.21) | 2017 | Modelled | IHME |
| 7.06 (6.76 - 7.39) | 2016 | Modelled | IHME |
| 7.25 (6.92 - 7.62) | 2015 | Modelled | IHME |
| 7.41 (7.08 - 7.80) | 2014 | Modelled | IHME |
| 7.56 (7.20 - 7.97) | 2013 | Modelled | IHME |
| 7.71 (7.35 - 8.13) | 2012 | Modelled | IHME |
| 7.86 (7.48 - 8.30) | 2011 | Modelled | IHME |
| 8.02 (7.60 - 8.51) | 2010 | Modelled | IHME |
| 8.18 (7.77 - 8.68) | 2009 | Modelled | IHME |
| 8.35 (7.91 - 8.84) | 2008 | Modelled | IHME |
| 8.53 (8.06 - 9.04) | 2007 | Modelled | IHME |
| 8.71 (8.21 - 9.24) | 2006 | Modelled | IHME |
| 8.88 (8.34 - 9.47) | 2005 | Modelled | IHME |
| 9.07 (8.50 - 9.66) | 2004 | Modelled | IHME |
| 9.25 (8.66 - 9.86) | 2003 | Modelled | IHME |
| 9.44 (8.82 - 10.09) | 2002 | Modelled | IHME |
| 9.62 (8.95 - 10.30) | 2001 | Modelled | IHME |
| 9.8 (9.09 - 10.53) | 2000 | Modelled | IHME |
| 9.98 (9.24 - 10.75) | 1999 | Modelled | IHME |
| 10.16 (9.42 - 10.95) | 1998 | Modelled | IHME |
| 10.33 (9.56 - 11.16) | 1997 | Modelled | IHME |
| 10.5 (9.70 - 11.35) | 1996 | Modelled | IHME |
| 10.66 (9.81 - 11.55) | 1995 | Modelled | IHME |
| 10.81 (9.94 - 11.72) | 1994 | Modelled | IHME |
| 10.95 (10.07 - 11.88) | 1993 | Modelled | IHME |
| 11.09 (10.18 - 12.06) | 1992 | Modelled | IHME |
| 11.23 (10.28 - 12.23) | 1991 | Modelled | IHME |
| 11.36 (10.34 - 12.41) | 1990 | Modelled | IHME |
| 6.24 (4.91 - 7.84) | 2015 | Modelled | WHO |
| 10.79 (10.29 - 11.31) | 2013 | Modelled | Schweitzer et al, 2015 |
| 8.2 (7.30 - 10.30) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 10.79 (10.29 - 11.31) | 2013 | Modelled | Schweitzer et al, 2015 |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.72 (0.56 - 0.93) | 2019 | Modelled | IHME |
| 0.78 (0.61 - 1) | 2018 | Modelled | IHME |
| 0.81 (0.62 - 1.03) | 2017 | Modelled | IHME |
| 0.82 (0.64 - 1.04) | 2016 | Modelled | IHME |
| 0.83 (0.64 - 1.04) | 2015 | Modelled | IHME |
| 0.88 (0.68 - 1.09) | 2014 | Modelled | IHME |
| 0.97 (0.76 - 1.20) | 2013 | Modelled | IHME |
| 1.08 (0.85 - 1.36) | 2012 | Modelled | IHME |
| 1.2 (0.93 - 1.50) | 2011 | Modelled | IHME |
| 1.29 (1 - 1.63) | 2010 | Modelled | IHME |
| 1.36 (1.05 - 1.71) | 2009 | Modelled | IHME |
| 1.41 (1.09 - 1.76) | 2008 | Modelled | IHME |
| 1.46 (1.14 - 1.82) | 2007 | Modelled | IHME |
| 1.53 (1.18 - 1.93) | 2006 | Modelled | IHME |
| 1.63 (1.25 - 2.05) | 2005 | Modelled | IHME |
| 1.89 (1.45 - 2.38) | 2004 | Modelled | IHME |
| 2.38 (1.82 - 2.99) | 2003 | Modelled | IHME |
| 3.01 (2.29 - 3.76) | 2002 | Modelled | IHME |
| 3.66 (2.79 - 4.59) | 2001 | Modelled | IHME |
| 4.26 (3.23 - 5.35) | 2000 | Modelled | IHME |
| 4.86 (3.74 - 6.05) | 1999 | Modelled | IHME |
| 5.52 (4.29 - 6.84) | 1998 | Modelled | IHME |
| 6.15 (4.80 - 7.57) | 1997 | Modelled | IHME |
| 6.68 (5.21 - 8.22) | 1996 | Modelled | IHME |
| 7 (5.44 - 8.68) | 1995 | Modelled | IHME |
| 7.19 (5.65 - 8.85) | 1994 | Modelled | IHME |
| 7.36 (5.75 - 9.09) | 1993 | Modelled | IHME |
| 7.5 (5.87 - 9.26) | 1992 | Modelled | IHME |
| 7.58 (5.89 - 9.42) | 1991 | Modelled | IHME |
| 7.62 (5.82 - 9.52) | 1990 | Modelled | IHME |
| 1.2 (0.84 - 1.62) | 2015 | Modelled | WHO |
| 2.2 (1.50 - 3.10) | 2011 | Survey/reported | WHO WPRO, Woodring J et al, 2017 |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 7,716,530 (7,023,370 - 8,433,260) | 1990 | Modelled | IHME |
| 7,778,240 (7,119,620 - 8,471,720) | 1991 | Modelled | IHME |
| 7,831,480 (7,187,440 - 8,509,790) | 1992 | Modelled | IHME |
| 7,876,850 (7,242,370 - 8,540,610) | 1993 | Modelled | IHME |
| 7,913,350 (7,278,950 - 8,581,850) | 1994 | Modelled | IHME |
| 7,939,340 (7,312,100 - 8,607,240) | 1995 | Modelled | IHME |
| 7,953,000 (7,346,260 - 8,601,240) | 1996 | Modelled | IHME |
| 7,952,080 (7,360,860 - 8,591,860) | 1997 | Modelled | IHME |
| 7,936,930 (7,360,760 - 8,556,920) | 1998 | Modelled | IHME |
| 7,909,460 (7,325,160 - 8,522,370) | 1999 | Modelled | IHME |
| 7,870,620 (7,300,650 - 8,454,930) | 2000 | Modelled | IHME |
| 7,820,600 (7,274,060 - 8,376,370) | 2001 | Modelled | IHME |
| 7,760,810 (7,251,780 - 8,296,520) | 2002 | Modelled | IHME |
| 7,694,380 (7,202,250 - 8,197,920) | 2003 | Modelled | IHME |
| 7,623,320 (7,151,620 - 8,119,610) | 2004 | Modelled | IHME |
| 7,551,640 (7,089,710 - 8,048,610) | 2005 | Modelled | IHME |
| 7,480,040 (7,052,840 - 7,941,240) | 2006 | Modelled | IHME |
| 7,404,910 (6,995,100 - 7,845,190) | 2007 | Modelled | IHME |
| 7,327,020 (6,940,890 - 7,754,680) | 2008 | Modelled | IHME |
| 7,249,140 (6,878,970 - 7,690,620) | 2009 | Modelled | IHME |
| 7,172,530 (6,802,100 - 7,609,620) | 2010 | Modelled | IHME |
| 7,100,540 (6,755,460 - 7,500,770) | 2011 | Modelled | IHME |
| 7,032,010 (6,700,490 - 7,416,260) | 2012 | Modelled | IHME |
| 6,960,420 (6,631,270 - 7,337,120) | 2013 | Modelled | IHME |
| 6,879,750 (6,573,130 - 7,240,590) | 2014 | Modelled | IHME |
| 6,784,720 (6,477,210 - 7,136,630) | 2015 | Modelled | IHME |
| 6,662,360 (6,378,840 - 6,970,680) | 2016 | Modelled | IHME |
| 6,540,060 (6,235,670 - 6,852,270) | 2017 | Modelled | IHME |
| 6,442,300 (6,173,590 - 6,731,060) | 2018 | Modelled | IHME |
| 6,360,160 (6,072,480 - 6,669,630) | 2019 | Modelled | IHME |
| 7,764,000 (6,863,000 - 9,745,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 7.89 (5.62 - 10.90) | 2019 | Modelled | IHME |
| 8.23 (5.96 - 11.20) | 2018 | Modelled | IHME |
| 8.22 (5.99 - 11) | 2017 | Modelled | IHME |
| 7.73 (5.68 - 10.30) | 2016 | Modelled | IHME |
| 7.25 (5.38 - 9.70) | 2015 | Modelled | IHME |
| 7.19 (5.38 - 9.58) | 2014 | Modelled | IHME |
| 7.26 (5.49 - 9.55) | 2013 | Modelled | IHME |
| 7.35 (5.57 - 9.60) | 2012 | Modelled | IHME |
| 7.49 (5.74 - 9.79) | 2011 | Modelled | IHME |
| 7.59 (5.90 - 9.78) | 2010 | Modelled | IHME |
| 7.67 (6.04 - 9.76) | 2009 | Modelled | IHME |
| 7.77 (6.20 - 9.75) | 2008 | Modelled | IHME |
| 7.96 (6.40 - 9.92) | 2007 | Modelled | IHME |
| 8.12 (6.51 - 9.98) | 2006 | Modelled | IHME |
| 8.32 (6.71 - 10.20) | 2005 | Modelled | IHME |
| 8.46 (6.76 - 10.60) | 2004 | Modelled | IHME |
| 8.59 (6.80 - 10.80) | 2003 | Modelled | IHME |
| 8.73 (6.89 - 11.10) | 2002 | Modelled | IHME |
| 8.91 (6.96 - 11.30) | 2001 | Modelled | IHME |
| 9.11 (6.98 - 11.60) | 2000 | Modelled | IHME |
| 9.42 (7.16 - 12.30) | 1999 | Modelled | IHME |
| 9.71 (7.31 - 12.80) | 1998 | Modelled | IHME |
| 9.98 (7.44 - 13.20) | 1997 | Modelled | IHME |
| 10.2 (7.59 - 13.80) | 1996 | Modelled | IHME |
| 10.4 (7.76 - 14) | 1995 | Modelled | IHME |
| 10.5 (7.87 - 14.20) | 1994 | Modelled | IHME |
| 10.7 (7.82 - 14.40) | 1993 | Modelled | IHME |
| 10.8 (7.81 - 14.50) | 1992 | Modelled | IHME |
| 10.9 (7.88 - 14.80) | 1991 | Modelled | IHME |
| 11 (7.91 - 14.90) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 7,603 (5,418 - 10,480) | 2019 | Modelled | IHME |
| 7,879 (5,711 - 10,711) | 2018 | Modelled | IHME |
| 7,820 (5,696 - 10,475) | 2017 | Modelled | IHME |
| 7,292 (5,364 - 9,747) | 2016 | Modelled | IHME |
| 6,794 (5,042 - 9,085) | 2015 | Modelled | IHME |
| 6,678 (4,998 - 8,898) | 2014 | Modelled | IHME |
| 6,683 (5,050 - 8,796) | 2013 | Modelled | IHME |
| 6,705 (5,082 - 8,757) | 2012 | Modelled | IHME |
| 6,766 (5,189 - 8,842) | 2011 | Modelled | IHME |
| 6,787 (5,275 - 8,752) | 2010 | Modelled | IHME |
| 6,797 (5,352 - 8,650) | 2009 | Modelled | IHME |
| 6,816 (5,437 - 8,554) | 2008 | Modelled | IHME |
| 6,908 (5,557 - 8,611) | 2007 | Modelled | IHME |
| 6,972 (5,596 - 8,575) | 2006 | Modelled | IHME |
| 7,074 (5,706 - 8,684) | 2005 | Modelled | IHME |
| 7,116 (5,682 - 8,883) | 2004 | Modelled | IHME |
| 7,146 (5,655 - 8,996) | 2003 | Modelled | IHME |
| 7,178 (5,665 - 9,099) | 2002 | Modelled | IHME |
| 7,244 (5,656 - 9,216) | 2001 | Modelled | IHME |
| 7,318 (5,608 - 9,327) | 2000 | Modelled | IHME |
| 7,470 (5,675 - 9,765) | 1999 | Modelled | IHME |
| 7,590 (5,715 - 9,999) | 1998 | Modelled | IHME |
| 7,680 (5,725 - 10,136) | 1997 | Modelled | IHME |
| 7,761 (5,747 - 10,443) | 1996 | Modelled | IHME |
| 7,753 (5,785 - 10,455) | 1995 | Modelled | IHME |
| 7,716 (5,765 - 10,431) | 1994 | Modelled | IHME |
| 7,667 (5,625 - 10,369) | 1993 | Modelled | IHME |
| 7,609 (5,516 - 10,237) | 1992 | Modelled | IHME |
| 7,547 (5,461 - 10,285) | 1991 | Modelled | IHME |
| 7,443 (5,373 - 10,145) | 1990 | Modelled | IHME |
| 20,102 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 39 (30 - 51) | 2019 | Modelled | IHME |
| 40 (30 - 50) | 2018 | Modelled | IHME |
| 40 (31 - 50) | 2017 | Modelled | IHME |
| 40 (30 - 50) | 2016 | Modelled | IHME |
| 40 (30 - 50) | 2015 | Modelled | IHME |
| 40 (31 - 51) | 2014 | Modelled | IHME |
| 41 (31 - 51) | 2013 | Modelled | IHME |
| 41 (32 - 52) | 2012 | Modelled | IHME |
| 42 (33 - 53) | 2011 | Modelled | IHME |
| 43 (34 - 53) | 2010 | Modelled | IHME |
| 43 (34 - 54) | 2009 | Modelled | IHME |
| 43 (34 - 54) | 2008 | Modelled | IHME |
| 44 (34 - 54) | 2007 | Modelled | IHME |
| 44 (34 - 54) | 2006 | Modelled | IHME |
| 44 (34 - 55) | 2005 | Modelled | IHME |
| 44 (34 - 55) | 2004 | Modelled | IHME |
| 44 (34 - 56) | 2003 | Modelled | IHME |
| 44 (34 - 56) | 2002 | Modelled | IHME |
| 44 (34 - 56) | 2001 | Modelled | IHME |
| 44 (34 - 57) | 2000 | Modelled | IHME |
| 45 (35 - 57) | 1999 | Modelled | IHME |
| 45 (35 - 57) | 1998 | Modelled | IHME |
| 46 (35 - 58) | 1997 | Modelled | IHME |
| 46 (36 - 58) | 1996 | Modelled | IHME |
| 46 (36 - 58) | 1995 | Modelled | IHME |
| 46 (36 - 58) | 1994 | Modelled | IHME |
| 46 (36 - 58) | 1993 | Modelled | IHME |
| 46 (35 - 58) | 1992 | Modelled | IHME |
| 46 (35 - 58) | 1991 | Modelled | IHME |
| 45 (35 - 58) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of HepB birth dose
Newborns
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 74 | 2018 | Survey/reported | WHO/UNICEF |
| 77 | 2017 | Survey/reported | WHO/UNICEF |
| 68 | 2016 | Survey/reported | WHO/UNICEF |
| 70 | 2015 | Survey/reported | WHO/UNICEF |
| 55 | 2014 | Survey/reported | WHO/UNICEF |
| 56 | 2013 | Survey/reported | WHO/UNICEF |
| 76 | 2012 | Survey/reported | WHO/UNICEF |
| 55 | 2011 | Survey/reported | WHO/UNICEF |
| 21 | 2010 | Survey/reported | WHO/UNICEF |
| 40 | 2009 | Survey/reported | WHO/UNICEF |
| 25 | 2008 | Survey/reported | WHO/UNICEF |
| 27 | 2007 | Survey/reported | WHO/UNICEF |
| 79 | 2019 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 75 | 2018 | Survey/reported | WHO/UNICEF |
| 94 | 2017 | Survey/reported | WHO/UNICEF |
| 96 | 2016 | Survey/reported | WHO/UNICEF |
| 97 | 2015 | Survey/reported | WHO/UNICEF |
| 95 | 2014 | Survey/reported | WHO/UNICEF |
| 59 | 2013 | Survey/reported | WHO/UNICEF |
| 97 | 2012 | Survey/reported | WHO/UNICEF |
| 95 | 2011 | Survey/reported | WHO/UNICEF |
| 88 | 2010 | Survey/reported | WHO/UNICEF |
| 94 | 2009 | Survey/reported | WHO/UNICEF |
| 87 | 2008 | Survey/reported | WHO/UNICEF |
| 67 | 2007 | Survey/reported | WHO/UNICEF |
| 93 | 2006 | Survey/reported | WHO/UNICEF |
| 94 | 2005 | Survey/reported | WHO/UNICEF |
| 94 | 2004 | Survey/reported | WHO/UNICEF |
| 78 | 2003 | Survey/reported | WHO/UNICEF |
| 89 | 2019 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 176 (142 - 231) | 2016 | Survey/reported | Larney S et al, 2017 |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HBV testing policy
Yes
Year of birth dose introduction
2005
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.66 (1.35 - 2) | 2019 | Modelled | IHME |
| 1.74 (1.41 - 2.10) | 2018 | Modelled | IHME |
| 1.77 (1.44 - 2.14) | 2017 | Modelled | IHME |
| 1.75 (1.43 - 2.10) | 2016 | Modelled | IHME |
| 1.73 (1.41 - 2.09) | 2015 | Modelled | IHME |
| 1.74 (1.42 - 2.09) | 2014 | Modelled | IHME |
| 1.75 (1.44 - 2.10) | 2013 | Modelled | IHME |
| 1.77 (1.46 - 2.12) | 2012 | Modelled | IHME |
| 1.79 (1.48 - 2.15) | 2011 | Modelled | IHME |
| 1.79 (1.48 - 2.16) | 2010 | Modelled | IHME |
| 1.79 (1.48 - 2.15) | 2009 | Modelled | IHME |
| 1.77 (1.48 - 2.12) | 2008 | Modelled | IHME |
| 1.75 (1.46 - 2.09) | 2007 | Modelled | IHME |
| 1.73 (1.45 - 2.06) | 2006 | Modelled | IHME |
| 1.73 (1.44 - 2.04) | 2005 | Modelled | IHME |
| 1.73 (1.44 - 2.04) | 2004 | Modelled | IHME |
| 1.73 (1.44 - 2.06) | 2003 | Modelled | IHME |
| 1.74 (1.44 - 2.10) | 2002 | Modelled | IHME |
| 1.76 (1.42 - 2.15) | 2001 | Modelled | IHME |
| 1.77 (1.42 - 2.21) | 2000 | Modelled | IHME |
| 1.84 (1.46 - 2.28) | 1999 | Modelled | IHME |
| 1.97 (1.56 - 2.45) | 1998 | Modelled | IHME |
| 2.12 (1.69 - 2.64) | 1997 | Modelled | IHME |
| 2.27 (1.80 - 2.82) | 1996 | Modelled | IHME |
| 2.36 (1.87 - 2.94) | 1995 | Modelled | IHME |
| 2.42 (1.93 - 3) | 1994 | Modelled | IHME |
| 2.47 (1.98 - 3.06) | 1993 | Modelled | IHME |
| 2.51 (2.02 - 3.10) | 1992 | Modelled | IHME |
| 2.54 (2.03 - 3.16) | 1991 | Modelled | IHME |
| 2.56 (2.04 - 3.17) | 1990 | Modelled | IHME |
| 1.1 (0.60 - 1.20) | 2015 | Modelled | Blach et al, 2017 |
| 1.1 (0.60 - 1.20) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Prevalence of anti-HCV
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 58.3 (42.70 - 74) | 2014 | Modelled | Degenhardt L et al, 2017 |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 1,735,980 (1,387,060 - 2,156,390) | 1990 | Modelled | IHME |
| 1,761,870 (1,409,620 - 2,187,590) | 1991 | Modelled | IHME |
| 1,774,650 (1,423,900 - 2,190,430) | 1992 | Modelled | IHME |
| 1,776,870 (1,426,070 - 2,202,190) | 1993 | Modelled | IHME |
| 1,770,950 (1,409,610 - 2,198,090) | 1994 | Modelled | IHME |
| 1,759,400 (1,397,040 - 2,194,020) | 1995 | Modelled | IHME |
| 1,716,800 (1,362,620 - 2,136,720) | 1996 | Modelled | IHME |
| 1,633,150 (1,297,980 - 2,030,910) | 1997 | Modelled | IHME |
| 1,536,320 (1,221,980 - 1,916,380) | 1998 | Modelled | IHME |
| 1,456,370 (1,160,970 - 1,803,550) | 1999 | Modelled | IHME |
| 1,424,800 (1,139,610 - 1,770,880) | 2000 | Modelled | IHME |
| 1,428,910 (1,157,660 - 1,746,380) | 2001 | Modelled | IHME |
| 1,434,630 (1,180,240 - 1,725,020) | 2002 | Modelled | IHME |
| 1,442,600 (1,197,970 - 1,711,970) | 2003 | Modelled | IHME |
| 1,453,200 (1,213,890 - 1,715,540) | 2004 | Modelled | IHME |
| 1,467,250 (1,228,060 - 1,737,810) | 2005 | Modelled | IHME |
| 1,489,250 (1,247,820 - 1,768,850) | 2006 | Modelled | IHME |
| 1,519,330 (1,266,910 - 1,814,330) | 2007 | Modelled | IHME |
| 1,552,080 (1,294,290 - 1,857,610) | 2008 | Modelled | IHME |
| 1,582,290 (1,309,790 - 1,902,780) | 2009 | Modelled | IHME |
| 1,604,200 (1,320,210 - 1,934,720) | 2010 | Modelled | IHME |
| 1,614,300 (1,334,140 - 1,939,340) | 2011 | Modelled | IHME |
| 1,616,250 (1,335,250 - 1,935,000) | 2012 | Modelled | IHME |
| 1,614,820 (1,327,200 - 1,934,940) | 2013 | Modelled | IHME |
| 1,615,160 (1,322,620 - 1,938,440) | 2014 | Modelled | IHME |
| 1,622,790 (1,323,740 - 1,961,440) | 2015 | Modelled | IHME |
| 1,651,870 (1,346,800 - 1,985,660) | 2016 | Modelled | IHME |
| 1,680,490 (1,368,460 - 2,032,910) | 2017 | Modelled | IHME |
| 1,661,610 (1,352,370 - 2,007,960) | 2018 | Modelled | IHME |
| 1,598,210 (1,298,300 - 1,931,150) | 2019 | Modelled | IHME |
| 1,066,000 (580,000 - 1,116,000) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 7.69 (5.32 - 10.60) | 2019 | Modelled | IHME |
| 7.38 (5.23 - 10.10) | 2018 | Modelled | IHME |
| 7.17 (5.10 - 9.77) | 2017 | Modelled | IHME |
| 7.07 (5.08 - 9.54) | 2016 | Modelled | IHME |
| 6.98 (5.04 - 9.37) | 2015 | Modelled | IHME |
| 6.75 (4.92 - 9.06) | 2014 | Modelled | IHME |
| 6.44 (4.74 - 8.55) | 2013 | Modelled | IHME |
| 6.1 (4.47 - 8.09) | 2012 | Modelled | IHME |
| 5.82 (4.35 - 7.71) | 2011 | Modelled | IHME |
| 5.6 (4.21 - 7.43) | 2010 | Modelled | IHME |
| 5.42 (4.09 - 7.15) | 2009 | Modelled | IHME |
| 5.24 (3.98 - 6.87) | 2008 | Modelled | IHME |
| 5.16 (3.91 - 6.71) | 2007 | Modelled | IHME |
| 5.12 (3.89 - 6.62) | 2006 | Modelled | IHME |
| 5.2 (3.92 - 6.70) | 2005 | Modelled | IHME |
| 5.3 (3.99 - 6.80) | 2004 | Modelled | IHME |
| 5.41 (4.09 - 7.01) | 2003 | Modelled | IHME |
| 5.54 (4.12 - 7.29) | 2002 | Modelled | IHME |
| 5.69 (4.24 - 7.50) | 2001 | Modelled | IHME |
| 5.85 (4.27 - 7.77) | 2000 | Modelled | IHME |
| 6.05 (4.41 - 8.10) | 1999 | Modelled | IHME |
| 6.19 (4.48 - 8.49) | 1998 | Modelled | IHME |
| 6.32 (4.52 - 8.70) | 1997 | Modelled | IHME |
| 6.44 (4.54 - 8.87) | 1996 | Modelled | IHME |
| 6.52 (4.56 - 9.09) | 1995 | Modelled | IHME |
| 6.61 (4.61 - 9.17) | 1994 | Modelled | IHME |
| 6.7 (4.64 - 9.38) | 1993 | Modelled | IHME |
| 6.8 (4.70 - 9.65) | 1992 | Modelled | IHME |
| 6.91 (4.74 - 9.84) | 1991 | Modelled | IHME |
| 6.99 (4.80 - 10) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 7,415 (5,128 - 10,185) | 2019 | Modelled | IHME |
| 7,064 (5,006 - 9,693) | 2018 | Modelled | IHME |
| 6,816 (4,852 - 9,288) | 2017 | Modelled | IHME |
| 6,672 (4,798 - 9,001) | 2016 | Modelled | IHME |
| 6,532 (4,721 - 8,777) | 2015 | Modelled | IHME |
| 6,268 (4,573 - 8,415) | 2014 | Modelled | IHME |
| 5,929 (4,360 - 7,875) | 2013 | Modelled | IHME |
| 5,568 (4,078 - 7,375) | 2012 | Modelled | IHME |
| 5,261 (3,926 - 6,970) | 2011 | Modelled | IHME |
| 5,012 (3,766 - 6,652) | 2010 | Modelled | IHME |
| 4,799 (3,625 - 6,332) | 2009 | Modelled | IHME |
| 4,596 (3,494 - 6,024) | 2008 | Modelled | IHME |
| 4,476 (3,393 - 5,830) | 2007 | Modelled | IHME |
| 4,398 (3,343 - 5,689) | 2006 | Modelled | IHME |
| 4,417 (3,332 - 5,693) | 2005 | Modelled | IHME |
| 4,456 (3,357 - 5,719) | 2004 | Modelled | IHME |
| 4,501 (3,405 - 5,834) | 2003 | Modelled | IHME |
| 4,554 (3,392 - 5,991) | 2002 | Modelled | IHME |
| 4,628 (3,444 - 6,095) | 2001 | Modelled | IHME |
| 4,697 (3,428 - 6,240) | 2000 | Modelled | IHME |
| 4,792 (3,492 - 6,418) | 1999 | Modelled | IHME |
| 4,841 (3,503 - 6,633) | 1998 | Modelled | IHME |
| 4,862 (3,483 - 6,695) | 1997 | Modelled | IHME |
| 4,876 (3,442 - 6,720) | 1996 | Modelled | IHME |
| 4,858 (3,400 - 6,775) | 1995 | Modelled | IHME |
| 4,840 (3,377 - 6,712) | 1994 | Modelled | IHME |
| 4,820 (3,334 - 6,745) | 1993 | Modelled | IHME |
| 4,802 (3,315 - 6,811) | 1992 | Modelled | IHME |
| 4,787 (3,284 - 6,818) | 1991 | Modelled | IHME |
| 4,751 (3,260 - 6,805) | 1990 | Modelled | IHME |
| 5,289 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 24 (15 - 35) | 2019 | Modelled | IHME |
| 24 (15 - 36) | 2018 | Modelled | IHME |
| 24 (15 - 36) | 2017 | Modelled | IHME |
| 25 (15 - 36) | 2016 | Modelled | IHME |
| 25 (15 - 36) | 2015 | Modelled | IHME |
| 25 (15 - 36) | 2014 | Modelled | IHME |
| 24 (15 - 35) | 2013 | Modelled | IHME |
| 24 (15 - 34) | 2012 | Modelled | IHME |
| 23 (14 - 34) | 2011 | Modelled | IHME |
| 23 (14 - 33) | 2010 | Modelled | IHME |
| 23 (14 - 34) | 2009 | Modelled | IHME |
| 23 (14 - 34) | 2008 | Modelled | IHME |
| 23 (14 - 34) | 2007 | Modelled | IHME |
| 23 (14 - 34) | 2006 | Modelled | IHME |
| 23 (14 - 34) | 2005 | Modelled | IHME |
| 23 (14 - 34) | 2004 | Modelled | IHME |
| 24 (14 - 34) | 2003 | Modelled | IHME |
| 24 (14 - 34) | 2002 | Modelled | IHME |
| 24 (14 - 35) | 2001 | Modelled | IHME |
| 24 (14 - 35) | 2000 | Modelled | IHME |
| 24 (14 - 35) | 1999 | Modelled | IHME |
| 24 (14 - 35) | 1998 | Modelled | IHME |
| 23 (14 - 34) | 1997 | Modelled | IHME |
| 23 (14 - 34) | 1996 | Modelled | IHME |
| 23 (14 - 34) | 1995 | Modelled | IHME |
| 23 (14 - 34) | 1994 | Modelled | IHME |
| 23 (14 - 34) | 1993 | Modelled | IHME |
| 24 (14 - 35) | 1992 | Modelled | IHME |
| 24 (14 - 35) | 1991 | Modelled | IHME |
| 24 (14 - 36) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 176 (142 - 231) | 2016 | Survey/reported | Larney S et al, 2017 |
Number of 28-pill count bottles exported from Indian manufacturers (SOF-based regimens)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 46,392 | 2016 | Survey/reported | CHAI HCV Market Report |
| 46,083 | 2017 | Survey/reported | CHAI HCV Market Report |
| 25,370 | 2018 | Survey/reported | CHAI HCV Market Report |
| 19,029 | 2019 | Survey/reported | CHAI HCV Market Report |
Showing out of
Show more
Price of HCV cure (Lowest average FOB price for 3 months of pangenotypic regimens)
National
Download| Value (US $) | Year | Type | Source |
|---|---|---|---|
| 387 | 2016 | Survey/reported | CHAI HCV Market Report |
| 285 | 2017 | Survey/reported | CHAI HCV Market Report |
| 177 | 2018 | Survey/reported | CHAI HCV Market Report |
| 195 | 2019 | Survey/reported | CHAI HCV Market Report |
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HBV testing policy
Yes
Year of birth dose introduction
2005
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
Overview
HBV elimination goal
Year of goal
2030
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Eligible for HBV generic medicines
Eligible for HCV generic medicines
